RecruitingPhase 3NCT05084196

Melatonin for Prevention of Kidney Injury

Melatonin for the Prevention of Antibiotic Associated Acute Kidney Injury


Sponsor

Rutgers, The State University of New Jersey

Enrollment

300 participants

Start Date

Jun 5, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria2

  • Aged 18 to 75 years
  • Currently prescribed vancomycin with the presumption that therapy will be continued for at least 3 days based on a review of subject status. Because of the critical nature of starting empiric broad-spectrum antibiotics, we will allow one dose of the antibiotic combination before consent and enrollment. This strategy is necessary for the ethical conduct of the study.

Exclusion Criteria10

  • Estimated creatinine clearance \< 30 mL/min
  • Liver impairment (liver enzymes \> 3 times upper limit)
  • Any history of allergy or contraindication to melatonin
  • Pregnancy or breastfeeding
  • Autoimmune disease
  • Requiring vasopressors
  • Requiring mechanical ventilation
  • History of acute kidney injury in the past 30 days
  • Inability to take oral medications
  • Clinical evidence of significant unstable or uncontrolled illness which, in the opinion of the research team, could confound the results of the study or put the patient at undue risk.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelatonin

Melatonin 5 mg capsule by mouth at bedtime

OTHERPlacebo Capsule

Placebo capsule by mouth at bedtime


Locations(2)

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Robert Wood Johnson University Hospital Somerset

Somerville, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05084196


Related Trials